Browse ALKBH8

Summary
SymbolALKBH8
NamealkB homolog 8, tRNA methyltransferase
Aliases MGC10235; TRM9; TRMT9; tRNA methyltransferase 9 homolog (S. cerevisiae); alkB, alkylation repair homolog 8 ( ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus Note=Predominantly cytoplasmic.
Domain PF13532 2OG-Fe(II) oxygenase superfamily
PF09004 Domain of unknown function (DUF1891)
PF08241 Methyltransferase domain
Function

Catalyzes the methylation of 5-carboxymethyl uridine to 5-methylcarboxymethyl uridine at the wobble position of the anticodon loop in tRNA via its methyltransferase domain (PubMed:20123966, PubMed:20308323). Catalyzes the last step in the formation of 5-methylcarboxymethyl uridine at the wobble position of the anticodon loop in target tRNA (PubMed:20123966, PubMed:20308323). Has a preference for tRNA(Arg) and tRNA(Glu), and does not bind tRNA(Lys)(PubMed:20308323). Binds tRNA and catalyzes the iron and alpha-ketoglutarate dependent hydroxylation of 5-methylcarboxymethyl uridine at the wobble position of the anticodon loop in tRNA via its dioxygenase domain, giving rise to 5-(S)-methoxycarbonylhydroxymethyluridine; has a preference for tRNA(Gly) (PubMed:21285950). Required for normal survival after DNA damage (PubMed:20308323). May inhibit apoptosis and promote cell survival and angiogenesis (PubMed:19293182).

> Gene Ontology
 
Biological Process GO:0001510 RNA methylation
GO:0002097 tRNA wobble base modification
GO:0002098 tRNA wobble uridine modification
GO:0006399 tRNA metabolic process
GO:0006400 tRNA modification
GO:0008033 tRNA processing
GO:0009451 RNA modification
GO:0030488 tRNA methylation
GO:0032259 methylation
GO:0034470 ncRNA processing
GO:0043414 macromolecule methylation
Molecular Function GO:0000049 tRNA binding
GO:0005506 iron ion binding
GO:0008168 methyltransferase activity
GO:0008173 RNA methyltransferase activity
GO:0008175 tRNA methyltransferase activity
GO:0008198 ferrous iron binding
GO:0016300 tRNA (uracil) methyltransferase activity
GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen
GO:0016706 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors
GO:0016741 transferase activity, transferring one-carbon groups
GO:0051213 dioxygenase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-74160: Gene Expression
R-HSA-6782315: tRNA modification in the nucleus and cytosol
R-HSA-72306: tRNA processing
Summary
SymbolALKBH8
NamealkB homolog 8, tRNA methyltransferase
Aliases MGC10235; TRM9; TRMT9; tRNA methyltransferase 9 homolog (S. cerevisiae); alkB, alkylation repair homolog 8 ( ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ALKBH8 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolALKBH8
NamealkB homolog 8, tRNA methyltransferase
Aliases MGC10235; TRM9; TRMT9; tRNA methyltransferase 9 homolog (S. cerevisiae); alkB, alkylation repair homolog 8 ( ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ALKBH8 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: 1.06; FDR: 0.009470 Sensitive to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolALKBH8
NamealkB homolog 8, tRNA methyltransferase
Aliases MGC10235; TRM9; TRMT9; tRNA methyltransferase 9 homolog (S. cerevisiae); alkB, alkylation repair homolog 8 ( ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ALKBH8 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1320.617
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3230.7
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0060.992
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0290.926
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1240.928
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0850.956
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0450.863
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2020.856
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1350.913
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0320.966
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5520.586
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0730.234
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ALKBH8 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolALKBH8
NamealkB homolog 8, tRNA methyltransferase
Aliases MGC10235; TRM9; TRMT9; tRNA methyltransferase 9 homolog (S. cerevisiae); alkB, alkylation repair homolog 8 ( ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ALKBH8. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolALKBH8
NamealkB homolog 8, tRNA methyltransferase
Aliases MGC10235; TRM9; TRMT9; tRNA methyltransferase 9 homolog (S. cerevisiae); alkB, alkylation repair homolog 8 ( ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ALKBH8. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ALKBH8.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolALKBH8
NamealkB homolog 8, tRNA methyltransferase
Aliases MGC10235; TRM9; TRMT9; tRNA methyltransferase 9 homolog (S. cerevisiae); alkB, alkylation repair homolog 8 ( ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ALKBH8. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolALKBH8
NamealkB homolog 8, tRNA methyltransferase
Aliases MGC10235; TRM9; TRMT9; tRNA methyltransferase 9 homolog (S. cerevisiae); alkB, alkylation repair homolog 8 ( ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ALKBH8 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolALKBH8
NamealkB homolog 8, tRNA methyltransferase
Aliases MGC10235; TRM9; TRMT9; tRNA methyltransferase 9 homolog (S. cerevisiae); alkB, alkylation repair homolog 8 ( ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ALKBH8 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolALKBH8
NamealkB homolog 8, tRNA methyltransferase
Aliases MGC10235; TRM9; TRMT9; tRNA methyltransferase 9 homolog (S. cerevisiae); alkB, alkylation repair homolog 8 ( ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ALKBH8 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.